Tango Therapeutics TNGX Discovery Direct Program Expenses-RD — Research And Development Expense

Other segment segments

Similar metrics at other companies

DNTHDiscovery Expenses — Research And Development Expense

$1.36M+51.4%

NUVLDiscovery Programs — Direct Expenses Related To Program

$2.8M+31.4%

SRRKRD Expense Srk439 — Research And Development Expense

$1.76M-58.9%

SRRKEarly Research — Research And Development Expense

$1.21M-16.8%

SRRKRD Expense Srk181 — Research And Development Expense

$36K-96.8%

ROIVOther development and discovery programs — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)

$13.43M-3.9%

Questions, answered.

What is Tango Therapeutics's discovery direct program expenses-rd — research and development expense?

Tango Therapeutics (TNGX) reported discovery direct program expenses-rd — research and development expense of $1.87M in Q1 2026.

How has Tango Therapeutics's discovery direct program expenses-rd — research and development expense changed year-over-year?

Tango Therapeutics's discovery direct program expenses-rd — research and development expense decreased by 60.0% year-over-year, from $4.68M to $1.87M.

What is the long-term trend for Tango Therapeutics's discovery direct program expenses-rd — research and development expense?

Over 3 years (2022 to 2025), Tango Therapeutics's discovery direct program expenses-rd — research and development expense has grown at a -29.3% compound annual growth rate (CAGR), from $28.76M to $10.17M.

What does discovery direct program expenses-rd — research and development expense mean?

This metric represents the direct research and development expenditures specifically allocated to the company's early-stage drug discovery programs. It captures the costs associated with identifying novel therapeutic targets and advancing preclinical candidates before they enter formal clinical development. Tracking these expenses provides insight into the company's investment intensity in its internal innovation pipeline and the sustainability of its long-term oncology research efforts.